DRG Market Assessment reports

Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Parkinson’s disease patient populations covering 171 countries and…

Clarivate Epidemiology’s coverage of Parkinson’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and…

Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…

Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…

Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…

Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…

Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…

Clarivate Epidemiology’s coverage of Parkinson’s disease (PD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence…

MARKET OUTLOOK Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug…

Since 2015, the genericized Parkinson’s disease (PD) market has witnessed the launch of nearly a dozen unique brands (e.g., Inbrija, Kynmobi, Nourianz), and several more are on the horizon,…

Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in early stages of the disease, today’s treatment paradigm is suboptimal owing to considerable pill burden, a…